Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

AI-based wearable sensors for continuous monitoring of diabetes and cardiovascular diseases

Project description

Transforming the management and outcomes of CVDs and diabetes

Cardiovascular diseases (CVDs) and diabetes pose a significant health threat, with CVDs alone responsible for 45 % of all deaths in Europe, and diabetes affecting 60 million people in the EU. The current reactive healthcare model falls short in preventing and managing these conditions effectively, leading to alarming mortality rates and escalating costs. The EU-funded SensCare project will propose a proactive approach. Unlike traditional healthcare models that primarily focus on treating symptoms after they have manifested, this approach prioritises early detection, intervention, and prevention. Tailored, non-invasive wearable monitoring devices will be developed to enable individuals to monitor their health continuously. This enables early detection, personalised interventions, and preventive measures.

Objective

Cardiovascular diseases (CVDs) are the leading cause of death in Europe, with a total of 3.9 million deaths yearly, accounting for 45% of all deaths. Diabetes is another widely spread disease affecting 60 million people in the EU (10% of the total population). Diabetes is the major cause of death in the age of 20-79. Also, Europe has the highest number of children with type-1 diabetes compared to other regions, with approximately 140,000 diagnosed children, and it has one of the highest prevalence rates of diabetes in children, with 21,600 new cases per year. Frequent glucose monitoring is critical for keeping blood glucose levels within a specific range to prevent potential cardiometabolic disease progression and pathophysiological changes. Current standard healthcare systems are passive and reactive, which deal with issues, incidents, and accidents after the opportunity to prevent damage to the patient has passed. With reactive healthcare, doctors provide treatment once patients contact them after developing noticeable symptoms. Actions are taken after things go wrong and sometimes after the opportunity to save the patient has passed. Besides, economically, reactive safety measures are costly in the long term. Moreover, this routine fails to prevent the onset of health conditions by prioritizing diagnostics and treatment.

SensAI aims to tackle the limitations of centralized and reactive healthcare systems by taking a proactive approach using tailored, non-invasive, and personalized solutions (wearable monitoring devices) specifically developed for diabetes and CVDs without affecting peoples’ daily routines.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-CSA - HORIZON Coordination and Support Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIE-2022-SCALEUP-02

See all projects funded under this call

Coordinator

SENSAI TEKNOLOJI ANONIM SIRKETI
Net EU contribution
€ 75 000,00
Address
RESITPASA MAH KATAR CAD ITU ARI TEKNO TEKNOKENT 4 BINASI BL 2 50 6 SARIYER
34469 Istanbul
Türkiye
Region
İstanbul İstanbul İstanbul
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data